562080-91-5

Usage

Uses

Used in Pharmaceutical Research and Development:
4-Bromo-2-iodoacetanilide is used as a building block for the production of various pharmaceutical drugs and agrochemicals. Its unique structure allows for the creation of complex organic molecules, making it an essential component in the development of new medications and chemical products.
Used in Organic Synthesis:
In the field of organic synthesis, 4-Bromo-2-iodoacetanilide serves as a precursor in the synthesis of complex organic molecules. Its reactivity with other compounds enables the formation of a variety of chemical structures, contributing to the advancement of organic chemistry.
Used in Research Laboratories:
4-Bromo-2-iodoacetanilide is commonly employed in research laboratories for its diverse applications in chemical synthesis and analysis. Its unique properties make it an important compound for conducting experiments and exploring new chemical reactions and processes.

Upstream product

• 66416-72-6 4-bromo-2-iodoaniline 
• 108-24-7 acetic anhydride 
• 75-36-5 acetyl chloride 
• 615-43-0 2-iodophenylamine 
• 103-84-4 Acetanilid 
• 103-88-8 4-bromoacetanilide 
• 106-40-1 4-bromo-aniline 

Downstream Products

• 5304-21-2 6-bromo-2-methylbenzothiazole 
• 1239440-04-0 4-(5-bromo-1H-indol-2-yl)-N-methylbenzenamine 
• 1239440-07-3 4-(5-bromo-1H-indol-2-yl)-N,N-dimethylbenzenamine 
• 851530-48-8 5-bromo-2-(4-methoxyphenyl)-1H-indole 
• 3939-23-9 3-bromo-10H-phenothiazine 
• 406161-72-6 N-[4-bromo-2-(3-chlorobenzoyl)phenyl]acetamide 
• 288391-74-2 6-bromo-4-(3-chloro-phenyl)-1H-quinolin-2-one 

Relevant academic research and scientific papers

Total synthesis of kealiiquinone: the regio-controlled strategy for accessing its 1-methyl-4-arylbenzimidazolone core

A practical, concise and straightforward total synthesis of kealiiquinone 1, a naphtho[2,3-d]imidazole alkaloid obtained from the Micronesian marine sponge Leucetta sp. was accomplished. The squaric acid chemistry to construct the 1,4-quinoid ring and the regioselective N-methylation through a benzo[c][1,2,5]selenadiazolium heterocycle are the key features in this report. The full details of the representative approaches involving the different attempted synthetic strategies are also presented. Finally a successful total synthesis of this complex secondary metabolite is described.

PtCl4-catalyzed cyclization of N-acetyl-2-alkynylanilines: A mild and efficient synthesis of N-acetyl-2-substituted indoles

An efficient synthesis of N-acetyl-2-substituted indole derivatives via direct intramolecular hydroamination of N-acetyl-2-alkynylaniline derivatives was developed. The reaction could be applied to a wide range of substrates employing only 1–2 mol% of PtCl4 as the catalyst to furnish the desired indole products in moderate to excellent yields. The current protocol is efficient, reliable and scalable, and could serve as an important tool for convenient and rapid access to this important class of N-heterocyclic skeleton from readily available substrates.

Cobalt(II)-catalyzed regioselective C-H halogenation of anilides

A cobalt-catalyzed regioselective C-H halogenation methodology is reported herein. The highlight of this work is the highly selective C-H functionalization of anilides, which results in high-yielding, versatile, and practical halogenated products. Thereby, brominations, chlorinations and iodinations of many electron-rich and electron-deficient anilides were achieved in a highly selective fashion. Mechanistic studies with respect to the pathway of the reaction are also described.

Monoprotected l-Amino Acid (l-MPAA), Accelerated Bromination, Chlorination, and Iodination of C(sp2)?H Bonds by Iridium(III) Catalysis

Halogenated arenes are important structural motifs commonly found in biologically active molecules and used for a variety of transformations in organic synthesis. Herein, we report the mono-protected l-amino acid (l-MPAA) accelerated iridium(III)-catalyzed halogenation of (hetero)anilides at room temperature. This reaction constitutes the first example of an iridium(III)/l-MPAA-catalyzed general halogenation of (hetero)arenes through C(sp2)?H activation. Furthermore, we demonstrate the potential utility of our method through its use in the synthesis of a quinolone derivative.

RADIOACTIVE IODINE LABELED STYRYL SUBSTITUTED AROMATIC HETEROCYCLIC COMPOUND

PROBLEM TO BE SOLVED: To provide a novel tau protein imaging agent that allows imaging of biological tau protein by a noninvasive, nuclear medical method. SOLUTION: The present invention provides a radioactive iodine labeled styryl substituted aromatic heterocyclic compound represented by a predetermined general formula or a salt thereof, or a radioactive medicine comprising the same. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

Structure-Activity Relationship Study of Heterocyclic Phenylethenyl and Pyridinylethenyl Derivatives as Tau-Imaging Agents That Selectively Detect Neurofibrillary Tangles in Alzheimers Disease Brains

In order to explore novel tau-imaging agents that can selectively detect neurofibrillary tangles in Alzheimers disease (AD) brains, we designed and synthesized a series of heterocyclic phenylethenyl and (3-pyridinyl)ethenyl derivatives with or without a dimethyl amino group. In in vitro autoradiography using AD brain sections, all radioiodinated ligands with a dimethyl amino group bound to Aβ deposits in the sections. In contrast, the ligands without a dimethyl amino group showed different patterns of radioactivity accumulation in the sections depending on the kind of heterocycle contained in their molecules. Particularly, a phenylethenyl benzimidazole derivative ([125I]64) showed marked radioactivity accumulation in the temporal lobe which corresponded with the distribution of tau deposits. [125I]64 also showed the most favorable pharmacokinetics in normal mouse brains (3.69 and 0.06% ID/g at 2 and 60 min postinjection, respectively) among all ligands in this study. Taken together, these results suggest that [123I]64 may be a new candidate tau-imaging agent.

Radioactive iodine labeled compound, and, radioactive pharmaceutical containing the same (by machine translation)

PROBLEM TO BE SOLVED: and compatibility and affinity for both amyloidosis acryloyldimethyltauric, labeled compd. radioactive iodine. SOLUTION: the present invention, N, N-labeled compd. dimethyl benzene amine including radioactive iodine or its salt. Selected drawing: no (by machine translation)

Synthesis and characterization of novel phenylindoles as potential probes for imaging of β-amyloid plaques in the brain

We synthesized a novel series of phenylindole (PI) derivatives and evaluated their biological activities as probes for imaging Aβ plaques in vivo. The affinity for Aβ plaques was assessed by an in vitro-binding assay using pre-formed synthetic Aβ aggregates. 2-Phenyl-1H-indole (2-PI) derivatives showed high affinity for Aβ42 aggregates with Ki values ranging from 4 to 32 nM. 2-PI derivatives clearly stained Aβ plaques in an animal model of AD. In biodistribution experiments using normal mice, 2-PI derivatives displayed sufficient uptake for imaging, ranging from 1.1% to 2.6% ID/g. Although additional modifications are necessary to improve uptake by and clearance from the brain, 2-PI derivatives may be useful as a backbone structure to develop novel Aβ imaging agents.

Phosphate transport inhibitors

Disclosed are compounds which have been identified as inhibitors of phosphate transport. Many of the compounds are represented by Structural Formula (I): Ar1—W—X—Y—Ar2; or a pharmaceutically acceptable salt thereof. Ar1 and Ar2 are independently a substituted or unsubstituted aryl group or an optionally substituted five membered or six membered non-aromatic heterocylic group fused to an optionally substituted monocylic aryl group. W and Y are independently a covalent bond or a C1-C3 substituted or unsubstituted alkylene group. X is a heteroatom-containing functional group, an aromatic heterocyclic group, substituted aromatic heterocyclic group, non-aromatic heterocyclic group, substituted non-aromatic heterocyclic group, an olefin group or a substituted olefin group. Also disclosed are methods of treating a subject with a disease associated with hyperphosphatemia, as well as a disease mediated by phosphate-transport function. The methods comprise the step of administering an effective amount of the one of the compounds described above.